Publications of Arjen NIKKELS
Bookmark and Share    
Full Text
See detailRisankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome
SENTERRE, Yseult ULiege; Jouret, Gaëlle ULiege; Collins, Patrick ULiege et al

in Dermatology and Therapy (2020), 10(4), 829-834

Risankizumab, an interleukin (IL)-23 antagonist, is a highly effective treatment for moderate to severe psoriasis. Crusted scabies (CS) is a rare and severe form of scabies, occurring mainly in ... [more ▼]

Risankizumab, an interleukin (IL)-23 antagonist, is a highly effective treatment for moderate to severe psoriasis. Crusted scabies (CS) is a rare and severe form of scabies, occurring mainly in immunosuppressed patients and/or neurologically or mentally ill patients. A young girl with Down syndrome was diagnosed with a hyperkeratotic form of psoriasis. As treatment with topical dermocorticosteroids, UVB-phototherapy and acitretin for 6 weeks did not improve the lesions, two injections of risankizumab were administered. Following these injections, the lesions became rapidly even more severely crusted, and new lesions appeared on the extremities and the face of the patient. There was histological evidence of a high charge of scabies, leading to a diagnosis of CS. The patient was hospitalized and successfully treated by local permethrine and systemic ivermectine. This case suggests that even though anti-IL23 antagonists display an excellent overall safety profile, a particular caution for infections should still be respected in patients with underlying risk factors. © 2020, The Author(s). [less ▲]

Detailed reference viewed: 25 (0 ULiège)
Full Text
See detailL'ALCOOL ET LA PEAU
FRANCHIMONT, Claudine ULiege; NIKKELS, Arjen ULiege; PIERARD, Gérald ULiege

in Revue Médicale de Liège (2019), 74(1), 1-6

Les manifestations cutanées en relation avec la consommation et l'abus d'alcool sont multiples. Il s'agit essentiellement de manifestations vasculaires et de signes cutanés en relation avec l'atteinte ... [more ▼]

Les manifestations cutanées en relation avec la consommation et l'abus d'alcool sont multiples. Il s'agit essentiellement de manifestations vasculaires et de signes cutanés en relation avec l'atteinte hépatique. La consommation d'alcool constitue, par ailleurs, un facteur aggravant de plusieurs maladies cutanées, dont le psoriasis, au cours duquel sa prévalence est élevée. D'autres répercussions cutanées, en relation avec la prise d'alcool, sont également discutées. [less ▲]

Detailed reference viewed: 145 (6 ULiège)
Full Text
See detailGranulomatous reactions from tattoos following BRAF inhibitor therapy
GIET, Gabrielle ULiege; LEBAS, Eve ULiege; RORIVE, Andrée ULiege et al

in Case Reports in Dermatology (2019), 11

Detailed reference viewed: 52 (5 ULiège)
Full Text
See detailPatient avec un carcinome spinocellulaire cutané localement avancé et métastatique traité par Cemiplimab
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue Médicale de Liège (2019), (74), 1-5

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de ... [more ▼]

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de l’aire ganglionnaire afférente. Malheureusement, certains cas ne sont plus opérables ou accessibles à la radiothérapie et un traitement systémique est alors indiqué. Les chimiothérapies sont peu efficaces et potentiellement toxiques. Une étude récente évaluant l’efficacité et la tolérance du cemiplimab, un antagoniste PD1, dans les cSCC localement avancés et métastasiques démontre une réponse objective confirmée de 49 % et de 47 %, respectivement, avec un maintien de la réponse d’au moins 6 mois de 63 % et de 60 %, respectivement. Nous présentons le cas d’un patient avec un cSCC localement avancé au niveau du front, avec effraction osseuse et adénopathies cervicales, ayant eu de multiples chirurgies et radiothérapies. Il a présenté une réponse partielle au cemiplimab avec un profil de tolérance satisfaisant. [less ▲]

Detailed reference viewed: 122 (7 ULiège)
Full Text
See detailCarcinome spinocellulaire cutané localement avancé et métastatique traité par cemiplimab.
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue medicale de Liege (2019), 74(7-8), 436-440

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes ... [more ▼]

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes. Unfortunately, some cases are no candidates for surgery or radiotherapy and a systemic treatment may be indicated. Chemotherapies are only partially efficacious and associated with potential toxicities. A recent study evaluating the efficacy and tolerance of cemiplimab, a PD1 antagonist for locally advanced and metastatic cSCC demonstrated an objective response rate of 49 % and 47 % for locally advanced and metastatic cSCC, while maintaining a response of at least 6 months of 63 % and 60 %, respectively. We present a clinical case of a patient with a locally advanced cSCC of the forehead with bone resorption and cervical lymphadenopathies. After failure of multiple surgical interventions and radiotherapies, he responded partially to cemiplimab immunotherapy with a good safety profile. [less ▲]

Detailed reference viewed: 214 (20 ULiège)
Full Text
See detailPolymorphous light eruption: Phototherapy-based desensitization versus intramuscular steroids - Who is right, who is wrong?
Libon, Florence ULiege; Nikkels, Arjen ULiege

in Dermatology (2018), 234(5-6), 192-193

Polymorphous light eruption (PLE) is an immunological mediated photo-dermatosis occurring in temperate regions that affects around 10–20% of the population, particularly between the second and third ... [more ▼]

Polymorphous light eruption (PLE) is an immunological mediated photo-dermatosis occurring in temperate regions that affects around 10–20% of the population, particularly between the second and third decades of life. Women are more often affected than men. The photo-distributed maculopapular eruption appears relatively rapidly after exposure to UV radiation and lasts for several days. Severe pruritus and general malaise may be observed. PLE has a serious impact on quality of life and patients are often afraid of being severely bothered during their holidays or leisure activities. [less ▲]

Detailed reference viewed: 41 (1 ULiège)
Full Text
See detailBiological treatment for psoriasis and the risk of herpes zoster: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Shalom, Guy; Naldi, Luigi; Lebwohl, Mark et al

in Journal of Dermatological Treatment (2018)

PURPOSE: To describe the risk of herpes zoster (HZ) in patients with psoriasis and its relation to non-biologic systemic therapies or biologic treatment. MATERIALS AND METHODS: Psoriasis Longitudinal ... [more ▼]

PURPOSE: To describe the risk of herpes zoster (HZ) in patients with psoriasis and its relation to non-biologic systemic therapies or biologic treatment. MATERIALS AND METHODS: Psoriasis Longitudinal Assessment and Registry (PSOLAR) is an international, prospective, registry that follows adult patients with psoriasis eligible to receive non-biologic systemic therapies or biologic therapies. Mutually exclusive therapy cohorts were defined. HZ incident rates were calculated for each therapy cohort and rates between cohorts were compared using hazard ratios (HR) adjusted for potential confounders, in new users and prevalent-exposure patients. RESULTS: A total of 55 HZ events were identified in 10,469 patients in PSOLAR. The adjusted hazard ratio in the overall study population (new user and prevalent-exposed patients) was 2.22 (95% CI: 0.82-5.97; p = 0.116) for tumor necrosis factor-alpha (TNF) inhibitors, 2.73 (0.98-7.58; p = 0.054) for ustekinumab, and 1.04 (0.20-5.41; p = 0.966) for methotrexate vs. reference (combined phototherapy, systemic steroids, topical therapy, and immunomodulators other than methotrexate). CONCLUSIONS: Exposure to ustekinumab, TNF-alpha inhibitors, and methotrexate was not associated with a statistically significant increased risk of HZ. However, HRs were elevated for ustekinumab and TNF-alpha inhibitors; a larger number of herpes zoster events would be needed to assess the presence or absence of risk. [less ▲]

Detailed reference viewed: 112 (1 ULiège)
Full Text
See detailMethyl-beta-cyclodextrin concurs with interleukin (IL)-4, IL-13 and IL-25 to induce alterations reminiscent of atopic dermatitis in reconstructed human epidermis.
De Vuyst, Evelyne; Giltaire, Severine; Lambert de Rouvroit, Catherine et al

in Experimental Dermatology (2018), 27(4), 435-437

Reconstructed human epidermis (RHE) mimic normal human in vivo epidermis in terms of histology, distribution of differentiation markers and barrier functionality. A typical transcriptional profile and the ... [more ▼]

Reconstructed human epidermis (RHE) mimic normal human in vivo epidermis in terms of histology, distribution of differentiation markers and barrier functionality. A typical transcriptional profile and the activation of signalling pathways reminiscent of atopic dermatitis (AD) lesional skin can be obtained in RHE upon incubation with methyl-β-cyclodextrin (MβCD), a molecule that extracts cholesterol from plasma membranes, thereby disrupting lipid microdomains. However, barrier function and morphology remain unaltered in those conditions, requiring further refinement of the model. [less ▲]

Detailed reference viewed: 86 (2 ULiège)
Full Text
See detailPachyderma in primary cutaneous NK and T-cell lymphoma and leukemia cutis
LEBAS, Eve ULiege; CHIAN, Cesar; TASSOUDJI, Nazli ULiege et al

in Case Reports in Dermatology (2017), 9(3), 151-157

Detailed reference viewed: 27 (2 ULiège)
Full Text
See detailRisk factors for skin infections in Mycosis Fungoides
LEBAS, Eve ULiege; NIKKELS, Arjen ULiege

Poster (2017, May 03)

Detailed reference viewed: 20 (1 ULiège)
Full Text
See detailLe mycosis fongoïde, le grand imitateur
LEBAS, Eve ULiege; NIKKELS, Arjen ULiege

in Skin (2017), 20(6), 6-10

Detailed reference viewed: 61 (3 ULiège)
Full Text
See detailLe mycosis fongoïdes : aspects diagnostiques et thérapeutiques axés sur la peau
LEBAS, Eve ULiege; NIKKELS, Arjen ULiege

in Skin (2017), 20(6), 12-17

Detailed reference viewed: 19 (1 ULiège)
Full Text
See detailL'image du mois: Souvenir de voyage.
COLSON, Fany ULiege; BOUFFLETTE, Nicolas ULiege; SOMJA, Joan ULiege et al

in Revue Médicale de Liège (2017), 72(10), 429-431

Clinical case no abstract available

Detailed reference viewed: 179 (6 ULiège)
Full Text
See detailQuel est l'interet des lasers de basse energie dans le traitement de l'alopecie androgeno-genetique ?
PAQUET, Philippe ULiege; ORDUZ, M.; FRANCHIMONT, Claudine ULiege et al

in Revue Médicale de Liège (2017), 72(12), 540-546

L’alopécie androgéno-génétique est une pathologie très fréquente du cuir chevelu, touchant aussi bien l’homme que la femme et amenant souvent une détresse psychologique intense. Les traitements ... [more ▼]

L’alopécie androgéno-génétique est une pathologie très fréquente du cuir chevelu, touchant aussi bien l’homme que la femme et amenant souvent une détresse psychologique intense. Les traitements médicamenteux (minoxidil topique, inhibiteurs de la 5-α réductase per os) ne sont pas constamment efficaces et peuvent induire des effets secondaires significatifs. Le traitement local par laser de basse énergie est susceptible d’améliorer les résultats thérapeutiques, tant dans l’alopécie androgéno-génétique masculine que féminine. Les modes d’action de ce type de traitement, les résultats obtenus à ce jour dans les principales études cliniques et les rares manifestations indésirables sont présentés ici. [less ▲]

Detailed reference viewed: 75 (2 ULiège)
Full Text
See detailEffect of Body Site and Surface on Vitamin D and 25-Hydroxyvitamin D Production after a Single Narrowband UVB Exposure
Libon, Florence ULiege; COURTOIS, Jessica ULiege; Le Goff, Caroline ULiege et al

in Journal of Investigative Dermatology (2017), 137(6), 1391-1393

[No abstract available]

Detailed reference viewed: 37 (6 ULiège)
Full Text
See detailHERPES ZOSTER IN PSORIASIS PATIENTS UNDERGOING TREATMENT WITH BIOLOGICAL AGENTS: PREVALENCE, IMPACT, AND MANAGEMENT CHALLENGES
EL HAYDERI, Lara ULiege; COLSON, Fany ULiege; DEZFOULIAN, Bita ULiege et al

in Psoriasis: Targets and Therapy (2016)

As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several ... [more ▼]

As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several studies and clinical experience provided evidence that the incidence of HZ increases by twofold to threefold in this patient category. The number of severe cases of HZ, with multisegmental, disseminated cutaneous, and/or systemic involvement, is also increased. Concerning psoriasis patients under biologicals, the clinician should be more alert for an eventual HZ event, in particular during the first year of biological treatment, and be aware of the possibility of more severe HZ cases. HZ may also undergo an age-shift toward younger patients. Rapid identification of risk factors for severe HZ, such as severe prodromal pains and/or the presence of satellite lesions, is recommended. The treatment recommendations of HZ in this patient group are identical to the recently published guidelines for the management of HZ. The live attenuated viral vaccine OKA/Merck strain anti-HZ vaccination is recommended before initiating biological treatment in psoriasis patients. The new adjuvanted anti-HZ vaccine will probably also benefit patients while on biological treatment. [less ▲]

Detailed reference viewed: 94 (4 ULiège)